Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Succinate dehydrogenase complex assembly factor 4 (SDHAF4) is a mitochondrial protein essential for the assembly of succinate dehydrogenase (SDH, also known as respiratory complex II), which performs a central role in both the tricarboxylic acid (TCA) cycle and the electron transport chain by coupling the oxidation of succinate to fumarate with reduction of ubiquinone[2][1]. SDHAF4 specifically binds the FAD-containing SDHA subunit, promotes its association with SDHB, and prevents excessive ROS generation by stabilizing assembly intermediates[2][1][3]. Loss of SDHAF4 compromises the activity of SDH, resulting in defects in mitochondrial respiration, accumulation of metabolic intermediates (like succinate), increased oxidative stress, and—depending on tissue context—can contribute to neurodegeneration, muscular dysfunction, and cardiac pathologies[1][3]. SDHAF4 has not been described as a direct therapeutic target or as modulated by approved drugs, but its dysfunction has been implicated in mitochondrial and cardiovascular diseases[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Succinate dehydrogenase complex assembly factor 4 (SDHAF4).